Apoptosis-induction is a novel therapeutic strategy for gastrointestinal and liver cancers

Current Gene Therapy

Volumn 15, Issue 2, 2015, Pages 193-200

  Wang, Fei ^a   Wang, Haizhong ^b   Sun, Xiaotian ^c,d,e   Li, Min ^d,e  

^a FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

^b LANZHOU GENERAL HOSPITAL   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

^d UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Apoptosis; Gastrointestinal cancer; liver cancer; Target therapy

Indexed keywords

APOPTOSOME; BORTEZOMIB; CASPASE 3; CASPASE 9; FAS ASSOCIATED DEATH DOMAIN PROTEIN; GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LENTIVIRUS VECTOR; OSTEOPONTIN; PROTEIN BCL 2; SURVIVIN; TUMOR NECROSIS FACTOR; TUMOR PROTEIN;

3' UNTRANSLATED REGION; APOPTOSIS; ARTICLE; B CELL LEUKEMIA; COLORECTAL CANCER; CYTOTOXICITY; DIGESTIVE SYSTEM CANCER; GENE TRANSFER; HUMAN; HUMAN CELL; INFLAMMATION; LIVER CANCER; LIVER CELL CARCINOMA; OXIDATIVE STRESS; PROTEIN EXPRESSION; RNA INTERFERENCE; TUMOR GROWTH; GASTROINTESTINAL NEOPLASMS; GENE THERAPY; GENETICS; LIVER NEOPLASMS; SIGNAL TRANSDUCTION;

APOPTOSIS; GASTROINTESTINAL NEOPLASMS; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; HUMANS; LIVER NEOPLASMS; NEOPLASM PROTEINS; SIGNAL TRANSDUCTION;

EID: 84952715509     PISSN: 15665232     EISSN: 18755631     Source Type: Journal    
DOI: 10.2174/1566523214666141224100801     Document Type: Article

References (70)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Wu WK, Wang XJ, Cheng AS, et al. Dysregulation and crosstalk of cellular signaling pathways in colon carcinogenesis. Crit Rev Oncol Hematol 2013;86:251-77.
3. Tejani MA, Saif MW. Pancreatic neuroendocrine tumors: does chemotherapy work? JOP 2014;15:132-4.
4. Marusawa H, Jenkins BJ. Inflammation and gastrointestinal cancer:an overview. Cancer Lett 2014; 345:153-6.
5. Plati J, Bucur O, Khosravi-Far R. Apoptotic cell signaling in cancer progression and therapy. Integr Biol (Camb) 2011;3:279-96.
6. Qiao L, Wong BC. Targeting apoptosis as an approach for gastrointestinal cancer therapy. Drug Resist Updat 2009;12:55-64.
7. Cui X, Zhang Y, Yang J, et al. ZIP4 confers resistance to zinc deficiency-induced apoptosis in pancreatic cancer. Cell Cycle 2014;13:1180-6.
8. Ouyang L, Shi Z, Zhao S, et al. Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis. Cell Prolif 2011;45:487-98.
9. Call JA, Eckhardt SG, Camidge DR. Targeted manipulation of apoptosis in cancer treatment. Lancet Oncol 2008;9:1002-11.
10. Zheng L, Lin X, Wu N, et al. Targeting cellular poptotic pathway with peptides from marine organisms. Biochim Biophys Acta 2013;1836:42-8.
11. Mukhopadhyay S, Panda PK, Sinha N, Das DN, Bhutia SK. Autophagy and apoptosis: where do they meet? Apoptosis 2014;19:555-66.
12. Bernardi S, Secchiero P, Zauli G. State of art and recent developments of anti-cancer strategies based on TRAIL. Recent Pat Anticancer Drug Discov 2012;7:207-17.
13. Sayers TJ. Targeting the extrinsic apoptosis signaling pathway for cancer therapy. Cancer Immunol Immunother 2011;60:1173-80.
14. Yerbes R, Palacios C, López-Rivas A. The therapeutic potential of TRAIL receptor signalling in cancer cells. Clin Transl Oncol 2011;13:839-47.
15. Szliszka E, Krol W. Polyphenols Isolated from Propolis Augment TRAIL-Induced Apoptosis in Cancer Cells. Evid Based Complement Alternat Med 2013;2013:731940.
16. Jia LT, Chen SY, Yang AG. Cancer gene therapy targeting cellular apoptosis machinery. Cancer Treat Rev 2012;38:868-76.
17. Martinez-Lostao L, Marzo I, Anel A, Naval J. Targeting the Apo2L/TRAIL system for the therapy of autoimmune diseases and cancer. Biochem Pharmacol 2012;83:1475-83.
18. Aronin A, Amsili S, Prigozhina TB, et al. Fn14•TRAIL effectively inhibits hepatocellular carcinoma growth. PLoS One 2013;8:e77050.
19. Maksimovic-Ivanic D, Stosic-Grujicic S, Nicoletti F, Mijatovic S. Resistanceto TRAIL and how to surmount it. Immunol Res 2012;52:157-68.
20. Koehler BC, Urbanik T, Vick B, et al. TRAIL-induced apoptosis of hepatocellular carcinoma cells is augmented by targeted therapies. World J Gastroenterol 2009;15:5924-35.
21. Wahl K, Siegemund M, Lehner F, et al. Increased apoptosis induction in hepatocellular carcinoma by a novel tumor-targeted TRAIL fusion protein combined with bortezomib. Hepatology 2013;57:625-36.
22. Omar HA, Arafa el-SA, Maghrabi IA, Weng JR. Sensitization of hepatocellular carcinoma cells to Apo2L/TRAIL by a novel Akt/NF-κB signalling inhibitor. Basic Clin Pharmacol Toxicol 2014;114:464-71.
23. Cao X, Yang M, Wei RC, et al. Cancer targeting Gene-Viro-Therapy of liver carcinoma by dual-regulated oncolytic adenovirus armed with TRAIL gene. Gene Ther 2011;18:765-77.
24. Melis MH, Simpson KL, Dovedi SJ, et al. Sustained tumour eradication after induced caspase-3 activation and synchronous tumour apoptosis requires an intact host immune response. Cell Death Differ 2013;20:765-73.
25. Vijayarathna S, Oon CE, Jothy SL, Chen Y, Kanwar JR, Sasidharan S. MicroRNA pathways: an emerging role in identification of therapeutic strategies Curr GeneTher 2014;14:112-20.
26. Drakaki A, Hatziapostolou M, Iliopoulos D. Therapeutically targeting microRNAs in liver cancer. Curr Pharm Des 2013;19:1180-91.
27. Khurana B, Goyal AK, Budhiraja A, Arora D, Vyas SP. siRNA delivery using nanocarriers - an efficient tool for gene silencing. Curr Gene Ther 2010;10:139-55.
28. Wang K, Lin B. Inhibitor of apoptosis proteins (IAPs) as regulatory factors of hepatic apoptosis. Cell Signal 2013;25:1970-80.
29. Saleem M, Qadir MI, Perveen N, et al. Inhibitors of apoptotic proteins: new targets for anticancer therapy. Chem Biol Drug Des 2013;82:243-51.
30. Guicciardi ME, Werneburg NW, Bronk SF, et al. Cellular inhibitor of apoptosis (cIAP)-mediated ubiquitination of phosphofurinacidic cluster sorting protein 2 (PACS-2) negatively regulates tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) cytotoxicity. PLoS One 2014;9:e92124.
31. Hernandez JM, Farma JM, Coppola D, et al. Expression of the antiapoptotic protein survivin in colon cancer. Clin Colorectal Cancer 2011;10:188-93.
32. Liu W, Zhu F, Jiang Y, Sun D, Yang B, Yan H. siRNA targeting survivin inhibitsthe growth and enhances the chemosensitivity of hepatocellular carcinoma cells. Oncol Rep 2013;29:1183-8.
33. Li G, Chang H, Zhai YP, Xu W. Targeted silencing of inhibitors of apoptosis proteins with siRNAs: a potential anti-cancer strategy for hepatocellular carcinoma. Asian Pac J Cancer Prev 2013;14:4943-52.
34. Zhang R, Ma L, Zheng M, et al. Survivin knockdown by short hairpin RNA abrogates the growth of human hepatocellular carcinoma xenografts in nude mice. Cancer Gene Ther 2010;17:275-88.
35. Arora R, Shuda M, Guastafierro A, et al. Survivin is a therapeutic target in Merkel cell carcinoma. Sci Transl Med 2012;4:133ra56.
36. Kelly RJ, Thomas A, Rajan A, et al. A phase I/II study of sepantronium bromide (YM155, surviving suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer. Ann Oncol 2013;24:2601-6.
37. Lennerz V, Gross S, Gallerani E, et al. Immunologic response to the survivin-derived multi-epitope vaccineEMD640744 in patients with advanced solid tumors. Cancer Immunol Immunother 2014;63:381-94.
38. Tolcher AW, Quinn DI, Ferrari A, et al. A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration- resistant taxane-pretreated prostate cancer. Ann Oncol 2012;23:968-73.
39. Mátrai J, Chuah MK, Vanden Driessche T. Recent advances in lentiviral vector development and applications. Mol Ther 2010;18:477-90
40. Ye F, Zhong B, Dan G, et al. Therapeutic anti-tumor effect of exogenous apoptin driven by human survivin gene promoter in a lentiviral construct. Arch Med Sci 2013;9:561-8.
41. Oh BY, Lee RA, Kim KH. siRNA targeting Livin decreases tumor in a xenograft model for colon cancer. World J Gastroenterol 2011;17:2563-71.
42. Wang X, Xu J, Ju S, Ni H, Zhu J, Wang H. Livin gene plays a role in drug resistance of colon cancer cells. Clin Biochem 2010;43:655-60.
43. Kim DK, Alvarado CS, Abramowsky CR, et al. Expression of inhibitor-of-apoptosis protein(IAP) livin by neuroblastoma cells:correlation with prognostic factors and outcome. Pediatr Dev Pathol 2005;8:621-9.
44. Qi W, Liang W, Jiang H, Miuyee WM. The function of miRNA in hepatic cancer stem cell. Biomed Res Int 2013;2013:358902.
45. Du L, Pertsemlidis A. microRNA regulation of cell viability and drug sensitivity in lung cancer. Expert Opin Biol Ther 2012;12:1221-39.
46. Humeau M, Torrisani J, Cordelier P. miRNA in clinical practice:pancreatic cancer. Clin Biochem 2013;46:933-6.
47. Segura MF, Greenwald HS, Hanniford D, Osman I, Hernando E. MicroRNA and cutaneous melanoma: from discovery to prognosis and therapy. Carcinogenesis 2012;33:1823-32.
48. Gao P, Sun L, He X, Cao Y, Zhang H. MicroRNAs and the Warburg Effect: new players in an old arena. Curr Gene Ther 2012;12:285-91
49. Sun BS, Dong QZ, Ye QH, et al. Lentiviral-mediated miRNA against osteopontin suppresses tumor growth and metastasis of human hepatocellular carcinoma. Hepatology 2008;48:1834-42.
50. Cheng Q, Cao X, Yuan F, Li G, Tong T. Knockdown of WWP1 inhibits growth and induces apoptosis in hepatoma carcinoma cells through the activation of caspase3 and p53. Biochem Biophys Res Commun 2014;448:248-54.
51. Akl H, Vervloessem T, Kiviluoto S, et al. A dual role for the antiapoptotic Bcl-2 protein in cancer: mitochondria versus endoplasmic reticulum. Biochim Biophys Acta 2014;1843:2240-52.
52. Czabotar PE, Lessene G, Strasser A, Adams JM. Control of apoptosis by theBCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol 2014;15:49-63.
53. Kelly PN, Strasser A. The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy. Cell Death Differ 2011;18:1414-24.
54. Juin P, Geneste O, Gautier F, Depil S, Campone M. Decoding and unlocking theBCL-2 dependency of cancer cells. Nat Rev Cancer 2013;13:455-65.
55. Wu J, Liu X, Cai H, Wang Y. Prediction of tumor recurrence after curative resection in gastric carcinoma based on bcl-2 expression. World J Surg Oncol 2014;12:40.
56. Cardoso MM, Peça IN, Roque AC. Antibody-conjugated nanoparticles for therapeutic applications. Curr Med Chem 2012;19:3103-27.
57. Samarasinghe RM, Gibbons J, Kanwar RK, Kanwar JR. Nanotechnology based platforms for survivin targeted drug discovery. Expert Opin Drug Discov 2012;7:1083-92.
58. Shapira A, Livney YD, Broxterman HJ, Assaraf YG. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance. Drug Resist Updat 2011;14:150-63.
59. Murad JP, Lin OA, Espinosa EV, Khasawneh FT. Current and experimental antibody-based therapeutics: insights, breakthroughs, setbacks and future directions. Curr Mol Med 2013;13:165-78.
60. Kumar M, Gupta D, Singh G, et al. Novel polymeric nanoparticles for intracellular delivery of peptide Cargos: antitumor efficacy of the BCL-2 conversion peptide NuBCP-9. Cancer Res 2014;74:3271-81.
61. Geng M, Wang L, Li P. Correlation between chemosensitivity to anticancer drugs and Bcl-2 expression in gastric cancer. Int J Clin Exp Pathol 2013;6:2554-9.
62. Han HJ, Kwon HY, Sohn EJ, et al. Suppression of E-cadherin mediates gallotannin induced apoptosis in Hep G2 hepatocelluar carcinoma cells. Int J Biol Sci 2014;10:490-9.
63. Fu J, Chen H, Soroka DN, Warin RF, Sang S. Cysteine-conjugated metabolites of ginger components, shogaols, induce apoptosis through oxidative stress-mediatedp53 pathway in human colon cancer cells. J Agric Food Chem 2014;62:4632-42.
64. Jiang Y, Turgeon DK, Wright BD, et al. Effect of ginger root on cyclooxygenase-1 and 15-hydroxyprostaglandin dehydrogenase expression in colonic mucosa of humans at normal and increased risk for colorectal cancer. Eur J Cancer Prev 2013;22:455-60.
65. Citronberg J, Bostick R, Ahearn T, et al. Effects of ginger supplementation on cell-cycle biomarkers in the normal-appearing colonic mucosa of patients at increased risk for colorectal cancer: results from a pilot, randomized, and controlled trial. Cancer Prev Res (Phila) 2013;6:271-81.
66. Burrell RA, Swanton C. Tumour heterogeneity and the evolution of polyclonal drug resistance. Mol Oncol 2014;8:1095-111.
67. von Manstein V, Yang CM, Richter D, Delis N, Vafaizadeh V, Groner B. Resistance of Cancer Cells to Targeted Therapies Through the Activation of Compensating Signaling Loops. Curr Signal Transduct Ther 2013;8:193-202.
68. Yu P, Du Y, Cheng X, Yu Q, Huang L, Dong R. Expression of multidrug resistance-associated proteins and their relation to postoperative individualized chemotherapy in gastric cancer. World J Surg Oncol 2014;12:307.
69. Mao ZL, He SB, Sheng WH, Dong XQ, Yang JC. Adenovirusmediated ING4 expression reduces multidrug resistance of human gastric carcinoma cells in vitro and in vivo. Oncol Rep 2013;30:2187-94.
70. Gowda R, Jones NR, Banerjee S, Robertson GP. Use of Nanotechnology to Develop Multi-Drug Inhibitors for Cancer Therapy. J Nanomed Nanotechnol 2013;4.pii: 184.